Alteogen Inc.

Alteogen Inc. is a biopharmaceutical company headquartered in Daejeon, South Korea, founded in 2008. It is publicly traded on the KOSDAQ exchange under the ticker symbol 196170 (A196170). As of late 2025, Alteogen reported a trailing 12-month revenue of approximately $138.5 million to $152 million, with a market capitalization around $13 billion. The company employs approximately 145-161 individuals.

Alteogen focuses on developing and commercializing novel biologics, including long-acting biobetters, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars. Key platform technologies include Hybrozyme™ Technology (ALT-B4), which enables the conversion of high-volume intravenous (IV) drugs to more convenient subcutaneous (SC) injections; NexP™ Fusion Technology for developing long-acting therapeutic proteins; and NexMab™ ADC Technology for antibody-drug conjugates. The company generates revenue by developing and commercializing its own drug products and by licensing its technology platforms to pharmaceutical partners.

In terms of patent litigation, Alteogen Inc. primarily operates as an operating company defending its intellectual property. The company has one tracked case as a defendant before the Patent Trial and Appeal Board (PTAB). This posture reflects its defense of core technologies, particularly its Hybrozyme™ (ALT-B4) platform.

A notable legal context involves a patent dispute with rival Halozyme Therapeutics. Alteogen successfully defended against an Inter Partes Review (IPR) petition filed by Halozyme concerning Alteogen's U.S. Patent No. 12,221,638, which covers a method for manufacturing recombinant hyaluronidase (ALT-B4). This patent is critical for Alteogen's partnerships, including an exclusive license agreement with MSD (Merck & Co. outside North America) for the subcutaneous formulation of its immuno-oncology drug Keytruda, which utilizes ALT-B4. Alteogen has also secured other licensing deals for its ALT-B4 technology with companies like Biogen and Sandoz.